Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Capital Expenditures (2016 - 2025)

OptimizeRx's Capital Expenditures history spans 14 years, with the latest figure at $54000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 65.82% year-over-year to $54000.0; the TTM value through Sep 2025 reached $194000.0, down 19.17%, while the annual FY2024 figure was $338000.0, 288.51% up from the prior year.
  • Capital Expenditures for Q3 2025 was $54000.0 at OptimizeRx, up from $10000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $158000.0 in Q3 2024 and bottomed at $5000.0 in Q4 2023.
  • The 5-year median for Capital Expenditures is $26855.0 (2022), against an average of $36701.4.
  • The largest annual shift saw Capital Expenditures surged 7621.31% in 2021 before it tumbled 77.78% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $37757.0 in 2021, then crashed by 56.73% to $16338.0 in 2022, then tumbled by 69.4% to $5000.0 in 2023, then skyrocketed by 1960.0% to $103000.0 in 2024, then crashed by 47.57% to $54000.0 in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Capital Expenditures are $54000.0 (Q3 2025), $10000.0 (Q2 2025), and $27000.0 (Q1 2025).